5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
about
Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants.Medroxyprogesterone acetate antagonizes the effects of estrogen treatment on social and sexual behavior in female macaques.Serotonin2C receptors in the medial prefrontal cortex facilitate cocaine-induced dopamine release in the rat nucleus accumbensMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens.Pharmacological targeting of the serotonergic system for the treatment of obesityFunctional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cellsDevelopmental exposure of rats to chlorpyrifos leads to behavioral alterations in adulthood, involving serotonergic mechanisms and resembling animal models of depressionGrowth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target(1,2,3)Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal bone developmentA synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat.Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in human neocortex slices: involvement of 5-HT(2C) and 5-HT(1A) receptorsInfluence of the 5-HT(2C) receptor antagonist SB242,084 on behaviour produced by the 5-HT(2) agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in miceGenetic variation in cortico-amygdala serotonin function and risk for stress-related disease5-HT2C receptor desensitization moderates anxiety in 5-HTT deficient mice: from behavioral to cellular evidence.Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift.Improved learning and memory in aged mice deficient in amyloid beta-degrading neutral endopeptidase.Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive-Compulsive Disorder.The use of serotonergic drugs to treat obesity--is there any hope?Serotonin-2C receptor agonists decrease potassium-stimulated GABA release in the nucleus accumbens.Investigation of the role of 5-HT2 receptor subtypes in the control of the bladder and the urethra in the anaesthetized female rat.Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues.Dissecting impulsivity and its relationships to drug addictions.Neurogenetics of emotional reactivity to stress in animals.Activation of lumbosacral 5-HT2C receptors induces bursts of rhythmic activity in sympathetic nerves to the vas deferens in male rats.Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys by direct and indirect activation of 5-HT2C receptors.Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures.Innovative approaches for the development of antidepressant drugs: current and future strategiesDysregulated A to I RNA editing and non-coding RNAs in neurodegeneration.Serotonin2C Receptors and the Motor Control of Oral ActivityHypothesis-driven medication discovery for the treatment of psychostimulant addictionAssessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout modelsDynamic regulation of RNA editing of ion channels and receptors in the mammalian nervous system.Direct and indirect 5-HT receptor agonists produce gender-specific effects on locomotor and vertical activities in C57 BL/6J mice.Further pharmacological characterization of 5-HT(2C) receptor agonist-induced inhibition of 5-HT neuronal activity in the dorsal raphe nucleus in vivo.Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the substantia nigra.A systematic investigation of the differential roles for ventral tegmentum serotonin 1- and 2-type receptors on food intake in the rat.Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats.The atypical 5-HT2 receptor mediating tachycardia in pithed rats: pharmacological correlation with the 5-HT2A receptor subtype.
P2860
Q21144229-3D75939F-280F-415C-BA52-06AA7119F6FBQ24542881-39F2C801-889A-4BD8-B156-F79F97C12568Q24596784-9C5C83EF-C1EF-409F-8D23-3F372355A065Q24620764-0ABCB239-6AA7-4342-BD4B-819349A67481Q24658013-03E9D93E-19A8-49E0-8457-CA925AB29BC7Q24675490-D8D73398-3DC9-4C98-A601-E344F0E2ACAEQ24812812-DA5BF4E8-279A-4463-83EC-46A479BCF552Q26783258-90F777C7-F5F9-4322-8C15-36CF54FE1AFDQ27345064-64690E02-CF63-45BE-8FFE-7921BCFA00EDQ28344114-0CAEFA90-20ED-471A-819F-16434EB295ABQ28344624-3C136774-2063-4B7C-9959-0819012AF123Q28366550-A1F87725-F51B-4252-87B3-032452210102Q30484420-660C707E-F312-4CB0-93D5-7B86BBD6BEADQ30487278-A95898BD-2C7A-409F-9678-5051A6007E45Q30627964-15D7B4DC-0716-455C-980D-0C4B3B4E8406Q30906677-1D388FA3-DB12-47E0-AA78-9FE97A708D1EQ33412126-1ED67223-20F8-4FCE-AE71-6972599786F9Q33710789-D79A5FC9-02B3-401A-B521-E82FD1AE785BQ34712327-7CDC7165-DB5F-4569-97D9-EA6AA2221107Q34765276-E8D0FF0D-E86F-4961-824E-24CDE5B199B0Q34792786-D9DE069F-9BBD-4E9E-B1DE-BFE6CB1CAE99Q34962263-3F28646E-5993-4977-8E94-A9441072E45FQ35046675-428E3494-3611-466B-B606-FD95D5A2B6A9Q35180445-D3BBEEB5-59BF-48D4-9044-0162D2982B5CQ35236526-8ADD0137-88C6-485F-BBEE-D308B9439FD1Q35546420-B221C719-E1FA-4C72-AC87-696B6EEAC3C7Q35889437-B693B073-C742-4C74-8289-9535A3311B70Q35991747-0558C6C4-DE76-49F8-9CDD-16818A8F3FA5Q36401400-7F6B4F19-AC8B-41E9-9317-EA219B173DCBQ36550804-95B72585-23AC-4504-A7BB-A18B25F26CFAQ36798864-1935F81E-16AA-4768-9DF0-F2EA02B05D22Q37183687-5AE753FD-307C-426A-A187-7FC85CE449CEQ37206280-1EB0CF01-2D04-424D-B25C-CAF45BF56512Q37222025-E55BFD19-6CFD-4822-9515-E3E7CE86DEF8Q37402221-BDD7CDF2-F731-46DC-89FE-1C288A9D2B1EQ37481197-002D8A16-B551-42C3-BEE5-8B2F55F48D07Q37671124-F071A393-8D67-44ED-B7A3-6FF83AFC2E6CQ39587382-684EB68A-12E8-4FE5-B2FA-7FC2D792D91EQ41835936-369158C9-CB95-4B7B-9871-FA55CE550236Q41916507-118B1B33-52DD-407B-B3D0-D2D20EABDB66
P2860
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
description
1998 nî lūn-bûn
@nan
1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
@ast
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
@en
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
@nl
type
label
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
@ast
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
@en
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
@nl
prefLabel
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
@ast
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
@en
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
@nl
P2093
P1476
5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.
@en
P2093
Andrews JS
Berendsen HH
Broekkamp CL
P304
P407
P577
1998-08-01T00:00:00Z